Gene: SP2

6668
-
Sp2 transcription factor
protein-coding
17q21.32
Ensembl:ENSG00000167182 MIM:601801 Vega:OTTHUMG00000150196 UniprotKB:Q02086
NC_000017.11
PubMed
0   ANCO-SNPs
ND
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.741e-2 (AD)  7.724e-2 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GORASP10.893
ILF30.886
DNAJB120.881
FAM193A0.878
GANAB0.875
EWSR10.872
CSNK1E0.871
RNF400.868
THRAP30.867
VPS520.867

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.717
OR4F29-0.675
MTRNR2L9-0.321
MTRNR2L6-0.315
MTRNR2L10-0.281
HMHB1-0.271
KRTAP1-1-0.257
OR6C74-0.256
C17orf112-0.255
SLURP1-0.247

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of SP2 mRNA"20453058
C5724913-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol results in decreased expression of SP2 protein26194647
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of SP2 mRNA"18648102
C0275764-hydroxy-2-nonenal4-hydroxy-2-nonenal results in decreased expression of SP2 mRNA12419474
D020106AcrylamideAcrylamide results in increased expression of SP2 mRNA28959563
C044887beta-methylcholinebeta-methylcholine affects the expression of SP2 mRNA21179406
C006780bisphenol Abisphenol A affects the expression of SP2 mRNA21786754
C006780bisphenol Abisphenol A affects the expression of SP2 mRNA25181051
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of SP2 mRNA12419474
C018475butyraldehydebutyraldehyde results in decreased expression of SP2 mRNA26079696
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in increased expression of SP2 mRNA16934159
D003520CyclophosphamideCyclophosphamide results in decreased expression of SP2 mRNA27281708
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of SP2 mRNA27392435
C000944dicrotophosdicrotophos results in increased expression of SP2 mRNA28302478
C039281furanfuran results in decreased expression of SP2 mRNA25539665
D017313FenretinideFenretinide results in decreased expression of SP2 mRNA28973697
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of SP2 mRNA27392435
C008261lead acetatelead acetate results in increased expression of SP2 mRNA20542052
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of SP2 mRNA23103053
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SP2 mRNA"20188158
D011441PropylthiouracilPropylthiouracil results in decreased expression of SP2 mRNA24780913
D012822Silicon DioxideSilicon Dioxide results in increased expression of SP2 mRNA25351596
D012999SomanSoman results in increased expression of SP2 mRNA19281266
C021751tanshinonetanshinone results in decreased expression of SP2 mRNA15849732
D014520UrethaneUrethane results in increased expression of SP2 mRNA28818685
D014635Valproic AcidValproic Acid results in decreased expression of SP2 mRNA22083351
D002762CholecalciferolCholecalciferol results in increased expression of SP2 mRNA17170073

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IDA10744779  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-IBA21873635  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001078transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IDA10744779  
GO:0005515protein binding-IPI21516116  25416956  
GO:0042826histone deacetylase binding-IPI17827154  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IDA10744779  
GO:0006351transcription, DNA-templated-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-IBA21873635  
GO:0006357regulation of transcription by RNA polymerase II-TAS1341900  
GO:0006955immune response-TAS1341900  
GO:0035264multicellular organism growth-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26369651Impact of the introduction of standardised packaging on smokers' brand awareness and identification in Australia. (2015 Sep 15)Balmford JDrug Alcohol Rev
22418747Serum C-reactive protein level and prehypertension in two Asian populations. (2013 Apr)Sabanayagam CJ Hum Hypertens
21267537Serum C-reactive protein level and prediabetes in two Asian populations. (2011 Apr)Sabanayagam CDiabetologia